U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H19N4O8S2.Na
Molecular Weight 554.528
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFSULODIN SODIUM

SMILES

[Na+].[H][C@]12SCC(C[N+]3=CC=C(C=C3)C(N)=O)=C(N1C(=O)[C@H]2NC(=O)[C@@H](C4=CC=CC=C4)S([O-])(=O)=O)C([O-])=O

InChI

InChIKey=REACMANCWHKJSM-DWBVFMGKSA-M
InChI=1S/C22H20N4O8S2.Na/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12;/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34);/q;+1/p-1/t15-,17-,21-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C22H19N4O8S2
Molecular Weight 531.538
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/3536385 | http://www.229877.com/article/2013/0126/32350.html

Cefsulodin is a third-generation of cephalosporin antibiotic with a narrow spectrum of activity. It has a specific activity against Pseudomonas aeruginosa. Cefsulodin’s targets are bacterial penicillin binding proteins. Drug is indicated for the treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms. Cefsulodin appears to be well tolerated and relatively free of any significant toxicity except for nausea and vomiting.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rat. Human data not available

Originator

Curator's Comment: # Takeda Chemical Industries, Ltd.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Curative
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Curative
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Curative
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Curative
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Curative
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Curative
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Curative
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Intramuscular: 0.5-1 g daily in 2-4 divided doses Intravenous: 0.5-1 g. in severe cases up to 2 g.
Route of Administration: Other
In Vitro Use Guide
Cefsulodin was an effective bactericidal agent against P. aeruguiosa and S. aureus. An apparent decrease in the number of living bacteria was observed at a concentration of 6.25 ug/ml for P. aerugnosa U 31 and 3.13 ug/ml for S. aureus FDA 209- P.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:02:51 UTC 2023
Edited
by admin
on Fri Dec 15 15:02:51 UTC 2023
Record UNII
2D087186PY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFSULODIN SODIUM
MART.   USAN   WHO-DD  
USAN  
Official Name English
CGP-71741E
Code English
CEFSULODIN SODIUM [JAN]
Common Name English
4-Carbamoyl-1-[[(6R,7R)-2-carboxy-8-oxo-7-[(2R)-2-phenyl-2-sulfoacetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methylpyridinium hydroxide, inner salt, monosodium salt
Common Name English
CEFSULODIN SODIUM SALT [MI]
Common Name English
Cefsulodin sodium [WHO-DD]
Common Name English
CEFSULODIN SODIUM SALT
MI  
Common Name English
CEFSULODIN SODIUM [USAN]
Common Name English
CEFSULODIN SODIUM [MART.]
Common Name English
PYRIDINIUM, 4-(AMINOCARBONYL)-1-((2-CARBOXY-8-OXO-7-((PHENYLSULFOACETYL)AMINO)-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYL)-, HYDROXIDE, INNER SALT, MONOSODIUM SALT, (6R-(6.ALPHA.,7.BETA.(R*)))
Common Name English
ABBOTT-46811
Code English
TAKESULIN
Brand Name English
CGP-7174/E
Code English
NSC-758163
Code English
Classification Tree Code System Code
NCI_THESAURUS C357
Created by admin on Fri Dec 15 15:02:51 UTC 2023 , Edited by admin on Fri Dec 15 15:02:51 UTC 2023
Code System Code Type Description
ECHA (EC/EINECS)
257-692-4
Created by admin on Fri Dec 15 15:02:51 UTC 2023 , Edited by admin on Fri Dec 15 15:02:51 UTC 2023
PRIMARY
NCI_THESAURUS
C98228
Created by admin on Fri Dec 15 15:02:51 UTC 2023 , Edited by admin on Fri Dec 15 15:02:51 UTC 2023
PRIMARY
CAS
52152-93-9
Created by admin on Fri Dec 15 15:02:51 UTC 2023 , Edited by admin on Fri Dec 15 15:02:51 UTC 2023
PRIMARY
EPA CompTox
DTXSID6045585
Created by admin on Fri Dec 15 15:02:51 UTC 2023 , Edited by admin on Fri Dec 15 15:02:51 UTC 2023
PRIMARY
FDA UNII
2D087186PY
Created by admin on Fri Dec 15 15:02:51 UTC 2023 , Edited by admin on Fri Dec 15 15:02:51 UTC 2023
PRIMARY
EVMPD
SUB01133MIG
Created by admin on Fri Dec 15 15:02:51 UTC 2023 , Edited by admin on Fri Dec 15 15:02:51 UTC 2023
PRIMARY
MERCK INDEX
m3216
Created by admin on Fri Dec 15 15:02:51 UTC 2023 , Edited by admin on Fri Dec 15 15:02:51 UTC 2023
PRIMARY Merck Index
SMS_ID
100000084701
Created by admin on Fri Dec 15 15:02:51 UTC 2023 , Edited by admin on Fri Dec 15 15:02:51 UTC 2023
PRIMARY
RXCUI
267417
Created by admin on Fri Dec 15 15:02:51 UTC 2023 , Edited by admin on Fri Dec 15 15:02:51 UTC 2023
PRIMARY RxNorm
NSC
758163
Created by admin on Fri Dec 15 15:02:51 UTC 2023 , Edited by admin on Fri Dec 15 15:02:51 UTC 2023
PRIMARY
ChEMBL
CHEMBL1617285
Created by admin on Fri Dec 15 15:02:51 UTC 2023 , Edited by admin on Fri Dec 15 15:02:51 UTC 2023
PRIMARY
PUBCHEM
656644
Created by admin on Fri Dec 15 15:02:51 UTC 2023 , Edited by admin on Fri Dec 15 15:02:51 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY